BeiGene’s Brukinsa Among Nine Drugs To Win EU Marketing Thumbs Up

Tanezumab’s Modest Impact On Osteoarthritis Pain Draws Negative CHMP Opinion

A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval. 

3D illustration of files with schizophrenia diagnosis and treatment with antipsychotic medication and psychotherapy.
EMA OKs Longest Available Dosing Interval For An Antipsychotic Medication • Source: Alamy

The European Medicines Agency has recommended for EU-wide approval nine new drugs, including three orphan medicines – BeiGene’s Brukinsa (zanubrutinib) for treating Waldenström’s macroglobulinemia, Deciphera Pharmaceuticals’ Qinlock (ripretinib) for advanced gastrointestinal stromal tumor, and Amivas’ malaria drug, Artesunate Amivas.

Gavreto (pralsetinib), Roche/Blueprint Medicines’ treatment for non-small cell lung cancer (NSCLC), and Vumerity (diroximel fumarate), Biogen/Alkermes treatment...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography